Pia Renaudin, the newly appointed CEO of SciBase.
The new CEO of SciBase discusses her reasons for taking on the role, her background, and her vision for steering SciBase towards success.
For those who may not be familiar with your background, can you tell us a little about your professional and academic journey?
After completing my MBA from Gothenburg University, I started my professional journey as a sales representative for AstraZeneca, working with Losec. Since then, I have had more than 25 years in leading positions in the Healthcare industry. During those years I have mainly worked internationally, spending 7 years in France, and working for US organizations like BMS, Gilead Sciences, and Stryker. Most recently, I worked as CEO for Senzime.
My drive and passion are to build high-performing teams and organizations AND to drive sales. In Medtech, with the right foundation, you can really make a meaningful impact on people, patients, and healthcare.
“My drive and passion are to build high-performing teams and organizations AND to drive sales. In Medtech, with the right foundation, you can really make a meaningful impact on people, patients, and healthcare”.
What in the MedTech industry has attracted you?
Working in the MedTech industry provides a unique opportunity to positively impact physicians’ and patients’ lives, which is very rewarding. From a more professional standpoint, I enjoy working very closely with healthcare professionals, as you do in MedTech. Since they need you to provide support and training – you become partners. That partnership enables you to develop and improve products in close collaboration with healthcare professionals.
What was it about SciBase that made you take the CEO position?
Several things attracted me, the most important was the area of skin cancer, a fatal disease if not detected and treated early. Being able to provide physicians with a device that enables earlier detection of melanoma was important to me. The Nevisense product is unique – it was developed at the Karolinska Institute by Prof Stig Ollmar and is based on cutting-edge technology combined with AI. It is the only validated point-of-care device that can detect melanoma at an early stage.
What was your impression of SciBase before coming on board?
It is a well-managed company, which has developed and received approval for a fantastic Swedish innovation. The team is very talented and knowledgeable. In Germany, the launch of the product has been a success and now the focus will be on the US. I was in the US last week to meet with customers, they confirm the greatness of Nevisense and willingly will support on the reimbursement journey.
SciBase focuses on the US market; what in your background makes you suitable to bring this market to success?
While my international background and experience certainly play a role, the most crucial aspect is to create a successful and efficient organization, so the most important task is to build a great team and to set the right focus and priorities. We recently hired a new Commercial leader in the US with vast experience in the dermatology field and with reimbursement.
Apart from being the new CEO of SciBase, what are your other interests?
I enjoy working, so it occupies most of my time. However, when I do find moments away from my professional responsibilities, I enjoy spending time with my family and friends. I like traveling, with frequent visits to France, my second home country.